H.C. Wainwright Keeps a Buy Rating on Agile Therapeutics

By Carrie Williams

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX), with a price target of $10. The company’s shares closed yesterday at $5.15.

According to TipRanks.com, Livnat is a 1-star analyst with an average return of -4.0% and a 40.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Pernix Therapeutics, and Horizon Pharma Inc.

Currently, the analyst consensus on Agile Therapeutics is Strong Buy and the average price target is $8.67, representing a 68.3% upside.

In a report issued on October 10, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $8 price target.

Based on Agile Therapeutics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $0 and GAAP net loss of $7.45 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $7.8 million.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.